GlassScriptPhysician profile
Jeannette Jakus
NPI 1477711422
$79,262.11
in general payments reported to CMS, 2019-2025
27 companies · $41K in 2025
The $41K reported for 2025 was more than what 96% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,203 · 2020: $251 · 2021: $73.19 · 2022: $9,836 · 2023: $18K · 2024: $8,906 · 2025: $41K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $37K · Consulting Fee: $28K · Food and Beverage: $1,905 · Travel and Lodging: $991.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $37,100.00 |
| Consulting Fee | $27,903.83 |
| Food and Beverage | $1,904.50 |
| Travel and Lodging | $990.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $34,661.48 | 2019-2025 | Nemluvio |
| Incyte Corporation | $22,772.63 | 2022-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $7,535.07 | 2023-2025 | Zoryve |
| Abbvie INC. | $4,802.94 | 2019-2025 | |
| Ucb, INC. | $2,774.45 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $2,425.91 | 2022-2024 | Sotyktu |
| Pierre Fabre Pharmaceuticals, INC. | $2,000.00 | 2022 | |
| Janssen Biotech, INC. | $466.53 | 2019-2025 | Tremfya |
| Dermavant Sciences, INC. | $346.70 | 2022-2023 | Vtama |
| Janssen Scientific Affairs, LLC | $332.42 | 2019 | |
| Merz North America, INC. | $197.22 | 2019-2025 | |
| Lilly USA, LLC | $134.57 | 2019-2025 | Ebglyss |
| Abeona Therapeutics, INC. | $119.79 | 2025 | Zevaskyn |
| Genzyme Corporation | $98.32 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $97.36 | 2019-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $88.10 | 2019-2020 | |
| Organon LLC | $77.04 | 2025 | Vtama |
| Amgen INC. | $55.70 | 2020-2025 | |
| Regeneron Pharmaceuticals, INC. | $47.19 | 2024 | Dupixent |
| Regeneron Healthcare Solutions, INC. | $41.52 | 2020-2021 | |
| Nobelpharma America, LLC | $30.27 | 2025 | |
| Vyne Pharmaceuticals INC. | $29.91 | 2021 | |
| Chiesi USA, INC. | $27.22 | 2024 | Filsuvez |
| Leo Pharma INC. | $26.51 | 2023 | Adbry |
| Sanofi-Aventis U.S. LLC | $24.71 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.65 | 2024 | Spevigo |
| Celgene Corporation | $23.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeannette Jakus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.